【4565】そーせいG 460 【Novartis Q3 Results 2018: 10/18】

1 :山師さん@トレード中 :2018/10/04(木) 12:00:43.81 ID:v1COp3rc0.net
【4565】そーせいG 459 【HTL0018318臨床中断・MTL-CEBPA臨床最新情報発表】

VIPQ2_EXTDAT: checked:vvvvvv:1000:512:—-: EXT was configured

761 :山師さん@トレード中 :2018/10/15(月) 15:00:03.15 ID:vQVxVoJHa.net


167 :山師さん@トレード中 :2018/10/08(月) 11:47:51.75 ID:oeXFwsazd.net



148 :山師さん@トレード中 :2018/10/06(土) 20:03:44.64 ID:dZww+m8P0.net


567 :山師さん@トレード中 :2018/10/11(木) 20:16:53.55 ID:j4MopDSX0.net


412 :山師さん@トレード中 :2018/10/10(水) 15:29:17.16 ID:3OZ1H7cWH1010.net


762 :山師さん@トレード中 :2018/10/15(月) 15:00:22.54 ID:vQVxVoJHa.net


109 :山師さん@トレード中 :2018/10/05(金) 18:50:57.53 ID:HelbTQZBd.net


828 :山師さん@トレード中 :2018/10/16(火) 12:09:34.93 ID:HL4+D2T10.net


696 :山師さん@トレード中 :2018/10/13(土) 20:01:45.28 ID:krNHLQbH0.net

※SOSEI定時株主総会:「当社事業の飛躍的な拡大」:COPDフランチャイズ売上は順調推移・複数の共同開発プログラム保有・自社PLの迅速な拡充。日本から世界へ:新たなグローバルブランド(“Sosei Heptares”)へ統一:2018年内に運用開始。(6/22)
※Heptares: Changed to “Heptares is Based the New Research Facility (Steinmetz Building) of Granta Park (Cambridge) from August 2018”. (7/9up)
・The company is currently based in Welwyn Garden City; however, this role will be based at our brand-new research facility at Granta Park (Cambridge) from August 2018.
※Granta Park_HP: Complete Refurbishment of the Steinmetz Building for Heptares. (8/1)
※Miles Congreve (Heptares): My last day at BioPark (ttps://pbs.twimg.com/media/DjnXjo0X0AA2Ggq.jpg). bring on Granta Park, Cambridge! (8/2)
※Heptares_Twitter (Change Name): Heptares→”SoseiHeptares”. (8/6 Changed)
※Heptares_HP: Changed Contact: Heptares Therapeutics Ltd. BioPark, Broadwater Road, Welwyn Garden City, Hertfordshire, AL7 3AX, UK.→”Heptares Therapeutics Ltd. “Steinmetz Building, Granta Park, Great Abington, Cambridge, CB21 6DG, UK.” (9/8update)
※Heptares Host Event up: Cambridge New Therapeutics Forum (CamNTF) February Meeting (2019/2/13 18:00-20:00, Location: Granta Park): Richard Henderson, MRC LMB (18:10 Presenting), Stacey Southall, “Sosei Heptares” (18:55 Presenting). (9/20up, 10/6update)
※Granta Park: Registration is now open for this years Santa Run at Granta Park. (ttps://pbs.twimg.com/media/DovrzfhXsAAp5KM.jpg): Left Building (“Steinmetz Building, SoseiHeptares”). (10/5)
※Granta Park: Everyone is enjoying the atmosphere as the 10k runners continue to come in family day out. (ttps://pbs.twimg.com/media/Do5ixDaWwAIppik.jpg): Center Building(“Steinmetz Building, SoseiHeptares”). (10/7)

242 :山師さん@トレード中 :2018/10/09(火) 11:29:28.66 ID:gMHTl2340.net


171 :山師さん@トレード中 :2018/10/08(月) 19:43:37.29 ID:BwkRVgPCd.net


1007 :山師さん@トレード中 :2018/10/18(木) 10:44:48.58 ID:pRvQlQi3H.net


777 :山師さん@トレード中 :2018/10/15(月) 16:54:14.32 ID:6rsmdxeb0.net


58 :山師さん@トレード中 :2018/10/05(金) 08:19:38.54 ID:dqEi5dDR0.net

おはよう! カニ食いザルさん!

84 :山師さん@トレード中 :2018/10/05(金) 12:28:50.44 ID:dqEi5dDR0.net

3連休前の金曜日。 どーーーん と行ってみよう。

309 :山師さん@トレード中 :2018/10/09(火) 17:51:26.04 ID:Pr0AYOm6M.net


819 :山師さん@トレード中 :2018/10/16(火) 10:01:52.59 ID:lkHt58sOd.net


888 :山師さん@トレード中 :2018/10/17(水) 09:54:22.10 ID:C83h2Ngfa.net


734 :山師さん@トレード中 :2018/10/15(月) 10:31:50.22 ID:F2aVWLysd.net


850 :山師さん@トレード中 :2018/10/16(火) 21:34:15.07 ID:9s+WK1Y30.net

※Pluristem: Company Presentation July 2018. Critical Limb Ischemia (CLI): PLX-PAD: Single pivotal study (Japan). Collaboration with Fukushima Medical University: Evaluating PLX-R18 cells as a treatment for radiation damage to the gastrointestinal (GI) tract and bone marrow. (7/23update)
※Pluristem: “New patent in Japan- covers PLX-R18’s protection of the gastrointestinal (GI) tract from radiation exposure”. Recent data from Fukushima University shows PLX-R18 cells significantly increased survival and enhanced the recovery of the GI tract after radiation exposure (7/26)
※Pluristem Initiates Two Pivotal Phase III Studies in Israel. “Numerous Clinical Sites in Israel to join sites in the U.S. and Europe for Pivotal Phase III Studies of PLX-PAD Cell Therapy in the Treatment of Critical Limb Ischemia and Muscle Injury Following Hip Fracture”(8/8)
※Pluristem: “Last dat for the 2018 MHSRS Conference- Arik Eisenkraft, MD, MHA, Director of Homeland Defense Projects, at the Gaylord Palms Resort & Convention Center, Kissimmee, FL. Glad to attend and share data with U.S. and other international colleagues”. (8/23)
※Pluristem: “Does the Placenta Hold the Answer to One of Our Most Challenging Medical Problems? (Bloomberg)” (9/12up)
※Pluristem: FY 2018 Earnings: “SEC Filing: Annual Report”: Sosei CVC for commercialization of our PLX-PAD cell therapy product in Japan for CLI: We are still in discussions with Sosei CVC and other related investors in order to finalize the terms of a definitive agreement. (9/12)
※Pluristem: FY 2018 Earnings: “Financial Statements: FY 2018 (Fiscal Year Ended June 30, 2018)”. ttps://www.pluristem.com/wp-content/uploads/2018/09/PSTI_10K_June_30_2018_isa.pdf (9/13up)
※Pluristem: “Does the Placenta Hold the Answer to One of Our Most Challenging Medical Problems? (Bloomberg)”: PAD Awareness Month: “We are proud to lead the most promising solution for this serious medical roblem.” (9/13)
※Pluristem: “IRMC patient receives historic stem cell surgery” (The Indiana Gazette). A first for American medicine may have occurred on Sept. 12 at the Indiana Regional Medical Center. (9/23).
※Pluristem Therapeutics receives FDA orphan status for treatment of graft failure and incomplete hematopoietic recovery, following hematopoietic cell transplantation (HCT). (9/24)
※Pluristem Therapeutics Announces FDA Orphan Drug Designation for PLX cell therapy for the Treatment of Graft Failure and Incomplete Recovery Following Hematopoietic Cell Transplantation. (9/25)
※Pluristem Reports Fiscal 2018 Fourth Quarter Results and Provides Corporate Update. “September is Peripheral Artery Disease (PAD) awareness month.” (9/27)
※Pluristem: Lior Raviv, VP Development at Pluristem, for BWB TV at Biotech Week Boston- discusses the importance of process development and automation to the future of cell therapy manufacturing, as well as the potential of 3D production. Interview: “Cell therapy today is more of an art than a process” (9/30)
※Cell & Gene Therapy, London: “Becoming Cell Therapy Makers – Opportunities and Challenges in “in House” Manufacturing of Cell Therapy Products”: Lior Raviv, Vice President of Development, Pluristem. (10/10 Presented)
※Pluristem Therapeutics Announces Publication in JCSM of Two-Year Follow-Up Data from Phase I/II Study in Muscle Regeneration and European Clearance for Ongoing Phase III Study. PLX-PAD cells Demonstrated a Significant Increase in Muscle Volume and Strength. (10/10)

51 :山師さん@トレード中 :2018/10/04(木) 23:47:28.53 ID:ROh/MUkM0.net

ビックニュース 第三者割当増資 増資しかできないそーせいヘプタレス ヘプタレスリストラしろよ

476 :山師さん@トレード中 :2018/10/11(木) 08:15:26.80 ID:1BGc4gk3p.net

気配 大 暴 落


185 :山師さん@トレード中 :2018/10/09(火) 00:22:20.31 ID:1N49WAtba.net


847 :山師さん@トレード中:2018/10/16(火) 17:56:06.17 ID:R0RMk4fR.net


5 :山師さん@トレード中 :2018/10/04(木) 12:03:29.04 ID:v1COp3rc0.net

※MiNA Therapeutics: “Senior Translational Scientist”: “Looking for a top Translational Scientist to help drive development of transformational RNA medicines” (Expires: 2018/10/19). MiNA’s first clinical asset has successfully completed Phase 1 and MiNA is developing a pipeline. (8/20)
※MiNA Therapeutics_HP: New Video: “MiNA Therapeutics – RNA Activation” (ttp://minatx.com/rna-activation/#rna_section_two_video). (8/22up) ※MiNA Therapeutics: Check out our new video explaining how saRNA medicines work. (8/28)
※ClinicalTrials: Phase 1/2a, First-in-Human Safety and Tolerability Study of MTL-CEBPA in Patients With Advanced Liver Cancer (OUTREACH): Phase 2a Study Status Change: Primary Completion: 2018/9→”2019/3″, Study Completion: 2018/12→”2019/12″. (9/10update)
※米国特許出願(MiNA):”Sarna Compositions and Methods of Use”. (9/13公開)
※ILCA 2018: “First-in-Human, First-in-Class Phase I Study of MTL-CEBPA, a Small Activating RNA (saRNA) Targeting the Transcription Factor C/EBP-α inPatients with Advanced Liver Cancer” Debashis Sarker, Support from MiNA Therapeutics. (9/16 11:45 Presented)
・Conclusion: MTL-CEBPA therapy was well tolerated, shows evidence of target engagement and initial clinical responses in patients with advanced HCC. Updated results for the dose escalation will be presented. Clinical trial information: NCT02716012.
※MiNA Therapeutics: Announces Findings From MTL-CEBPA Clinical Trial in Patients with Advanced Liver Cancer at International Liver Cancer Association Conference. (9/19)
※SOSEI:「MiNA Therapeutics社が進行肝がん患者を対象にした小分子活性化RNA肝がん治療候補薬MTL-CEBPAの臨床試験についての最新情報を国際肝癌研究会(ILCA)年次総会で発表」。(9/19)
※欧州特許(MiNA):Albumin Production and Cell Proliferation. (9/19公開)

751 :山師さん@トレード中 :2018/10/15(月) 13:46:05.77 ID:Yi0iixzsd.net


273 :山師さん@トレード中 :2018/10/09(火) 13:54:22.14 ID:4euZhZde0.net


965 :山師さん@トレード中 :2018/10/18(木) 08:53:47.19 ID:0k0OhVgA0.net


240 :山師さん@トレード中 :2018/10/09(火) 11:07:09.42 ID:TkCXU6yj0.net


308 :山師さん@トレード中 :2018/10/09(火) 17:49:11.33 ID:Tm8rlcmwd.net


79 :山師さん@トレード中 :2018/10/05(金) 10:46:35.04 ID:DtLqagXEd.net


261 :山師さん@トレード中 :2018/10/09(火) 13:02:00.37 ID:yy1e+w2Gd.net


166 :山師さん@トレード中 :2018/10/08(月) 11:08:57.92 ID:AiIguyIU0.net


503 :山師さん@トレード中 :2018/10/11(木) 09:39:50.79 ID:jboH/J3Bd.net


52 :山師さん@トレード中 :2018/10/05(金) 00:31:03.21 ID:+L+s/jHj0.net

Heptares Patent update:
※米国特許出願(Heptares):CGRP Receptor Antagonists (US20180153876A1). (6/7公開)
※米国特許出願(Heptares):Muscarinic M1 Receptor Agonists. (6/7公開)
※米国特許出願(Heptares):Muscarinic Agonists (US20180155315A1). (6/7公開)
※欧州特許出願(Heptares):Muscarinic Agonists (EP3331528 A1 EP3331529 A1 EP3331869 A1). (6/13公開)
※欧州特許出願(Heptares):Mutant GPCRS. (6/13公開)
※欧州特許(Heptares):Bicyclic AZA Compounds as Muscarinic M1 Receptor Agonists. (6/27公開)
※米国特許出願(Heptares):Bicyclic AZA Compounds as Muscarinic M1 Receptor and/or M4 Receptor Agonists. (6/28公開)
※米国特許(Heptares):Piperidin-1-YL and Azepin-1-YL Carboxylates as Muscarinic M4 Receptor Agonists (Inventors: Takeda Cambridge & Heptares Therapeutics) (7/24公開)
※米国特許(Heptares):Muscarinic Receptor Agonists. (7/24公開)
※米国特許出願(Heptares):Muscarinic Agonists (US20180222885A1). (8/9公開)
※米国特許出願(Heptares):Muscarinic Agonists (US20180228791A1). (8/16公開)
※欧州特許(Heptares):Piperidin-1-YL and Azepin-1-YL Carboxylates as Muscarinic M4 Receptor Agonists (Inventors: Takeda Cambridge & Heptares Therapeutics). (8/22公開)
※欧州特許出願(Heptares):CGRP Receptor Antagonists (EP3368525A1, EP3368526A1, EP3368536A1). (9/5公開)
※欧州特許出願(Heptares):Oxime Compounds as Agonists of the Muscarinic M1 Receptor and/or M4 Receptor Agonists. (9/12公開)
※米国特許出願(Heptares):Bicyclic AZA Compounds as Muscarinic M1 Receptor Agonists. (9/13公開)
※欧州特許(Heptares):4-(3-Cyanophenyl)-6-Pyridinylpyrimidine mGLU5 Modulators. (9/26公開)

※国際特許出願(Heptares):”CGRP Receptor Antagonists”. (10/4公開)
・Document Type and Number: WIPO Patent Application WO/2018/178938 A1
・Publication Date: 2018/10/4
・Assignee: Heptares Therapeutics Limited
The disclosures herein relate to novel compounds of formula (IA) wherein R1, R2, R3 and R4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.
The disclosures herein also relates to novel compounds of formula(IB) wherein R1, R2 and R3 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.
The disclosures herein also relate to novel compounds of formula (IC) wherein Ar1 and R1 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.

717 :山師さん@トレード中 :2018/10/14(日) 11:59:34.68 ID:dgUULvdVd.net


226 :山師さん@トレード中 :2018/10/09(火) 10:03:06.33 ID:gKFGCoOep.net


953 :山師さん@トレード中 :2018/10/18(木) 06:01:46.15 ID:ycBYqP6/0.net

※Chris de Graaf (Heptares) 3時間前:”A minergic GPCR-Ligand Interactions: A Chemical and Structural Map of Receptor Mutation Data.” (10/17)

※Journal of Medicinal Chemistry: “Aminergic GPCR-Ligand Interactions: A Chemical and Structural Map of Receptor Mutation Data.” (10/17 Publicated)
(Marton Vass, Sabina Podlewska, Iwan J. P. De Esch, Andrzej J. Bojarski, Rob Leurs, Albert J. Kooistra, and Chris de Graaf) 3D-e-Chem NLeSC project
Publication Date (Web): October 17, 2018
The aminergic family of G protein-coupled receptors (GPCRs) plays an important role in various diseases and represents a major drug discovery target class.
Structure determination of all major aminergic subfamilies has enabled structure-based ligand design for these receptors.
Site-directed mutagenesis data provides an invaluable complementary source of information for elucidating the structural determinants of binding of different ligand chemotypes.
The current study provides a comparative analysis of 6692 mutation data points on 34 aminergic GPCR subtypes, covering the chemical space of 540 unique ligands from mutagenesis experiments,
and information from experimentally determined structures of 52 distinct aminergic receptor-ligand complexes.
The integrated analysis enables detailed investigation of structural receptor-ligand interactions and assessment of the transferability of combined binding mode and mutation data across ligand chemotypes and receptor subtypes.
An overview is provided of the possibilities and limitations of using mutation data to guide the design of novel aminergic receptor ligands.

375 :山師さん@トレード中 :2018/10/10(水) 11:54:41.85 ID:uQsvkRgt01010.net


267 :山師さん@トレード中 :2018/10/09(火) 13:32:52.81 ID:Tm8rlcmwd.net


201 :山師さん@トレード中 :2018/10/09(火) 08:38:07.96 ID:LOhUV06Cd.net


91 :山師さん@トレード中 :2018/10/05(金) 13:40:57.59 ID:w0mtTuw20.net


363 :山師さん@トレード中 :2018/10/10(水) 10:07:32.43 ID:KsSmcMZ+d1010.net


935 :山師さん@トレード中 :2018/10/17(水) 17:04:53.13 ID:Rc+jlyiya.net


339 :山師さん@トレード中 :2018/10/09(火) 23:48:30.64 ID:yy1e+w2Gd.net


296 :山師さん@トレード中 :2018/10/09(火) 15:35:55.47 ID:OLG2wK5Ra.net


941 :山師さん@トレード中 :2018/10/17(水) 23:50:33.08 ID:F8q8ytJMd.net


160 :山師さん@トレード中 :2018/10/07(日) 23:00:35.36 ID:L/9mEFtt0.net

※技術情報協会ペプチドスケールアップセミナー:「ペプチド原薬の化学合成技術とスケールアップ」JITSUBO(株) 研究開発部 部長 山崎貴史。(10/23 10:00〜12:00)
※Schrodinger Life Science User Meeting 2018, Boston: keynote “SBDD finally come of age: R(eal)I drives rational design, including FEP on GPCRs, with waters found key for binding, selectivity and kinetics – a 35 year perspective”: Jon Mason, Heptares. (10/23 9:15 Presenting)
※New York Area Group for Informatics and Modeling (NYAGIM) Event: “4 Decades of CADD in Pharma: A personal perspective of critical lessons learned from each decade that will enhance our ability to succeed in the future” Jon Mason, Heptares. (10/30 18:00 Presenting)
※BIO-Europe, Copenhagen, Denmark: Company Presentations, MiNA Therapeutics. (11/5-7 Presenting)
※AASLD Liver Meeting 2018, San Francisco: MiNA Therapeutics. (11/9-13)
※Jefferies London Healthcare Conference, London, UK: MiNA Therapeutics. (11/14-15)
※PSDI 2018 (26th Protein Structure Determination in Industry Meeting”), Versailles: Keynote Speaker: “A Decade of GPCR Structure-Based Drug Design – Structural insights into the allosteric control of GPCR activity”: Dr. Andrew S. Dore, Heptares. (11/11 21:00 Presenting)
※PCT: Partnerships in Clinical Trials Europe: “Use of molecular and functional Imaging in early clinical development: From target engagement to proof of concept”: Pradeep Nathan, Vice President, CNS Clinical Development and Experimental Medicine at Heptares. (11/28 16:00 Presenting)
※PREP UK 2018: Organising Committee: Kerry O’Hare, Lead Analytical and Purification Chemist, Heptares. (11/29-30)
・”Implementation of MP infrastructure at Heptares”: Kerry O’Hare, Heptares. (11/29 11:55 Presenting) ※10/6up
・”Session 3 – New Tricks”: Chair: Kerry O’Hare. (11/29 15:45 Session Chair) ※10/6up
・”Chrom Logd as part of compound management workflow”: Kerry O’Hare, Heptares. (11/30 10:05 Presenting) ※10/6up
※Cambridge New Therapeutics Forum (CamNTF) February Meeting (2019/2/13 18:00-20:00) (Host: Heptares. Location: Granta Park): Richard Henderson, MRC LMB (18:10 Presenting), Stacey Southall, “Sosei-Heptares”. (18:55 Presenting) ※10/6update
※SMi’s 10th Annual RNA Therapeutics Returns to London This February 2019: ”Small Activating RNA – from Bench to Bedside”: David Blakey, Chief Scientific Officer, MiNA Therapeutics. (2019/2/21 13:40 Presenting)

822 :山師さん@トレード中 :2018/10/16(火) 10:26:59.61 ID:VRx5tJPDd.net


867 :山師さん@トレード中 :2018/10/17(水) 07:11:50.34 ID:kEopcblUa.net